Biotech & Medtech
Biotech & Medtech news — Friday 13 November 2026
26 stories from 4 sources, every one in English. Each links to its publisher.
-
STAT+: Enforcement of stringent Medicaid work requirements delayed for six months
WASHINGTON — The Trump administration announced Friday that it is giving states an additional six months to begin enforcing Medicaid work requirements. States have been racing to prepare their Medicaid systems by Jan. 1 to include the work…
-
Zus Health Raises $33M to Make Healthcare More Connected
The Series B round was led by Drive Capital, with participation from Sanofi Ventures, HealthX Ventures, Alumni Ventures, Andreessen Horowitz (a16z), F-Prime, Maverick Ventures and JAZZ Venture Partners. The post Zus Health Raises $33M to…
-
STAT+: Democrats coalesce around ‘Medicare for More,’ ‘Medikids’ proposals
WASHINGTON — Democrats are coalescing around a plan to offer Medicare to more Americans, if not all of them. As the party navigates the pressure to quickly lower the cost of living, so-called Medicare for More is emerging as a consensus…
-
Biosensors and Wearables Among MedTech Showcased at INVEST Digital Health
[Sponsored] ARPA-H portfolio companies in the Innovation Showcase included biosensor and wearable startups to monitor vital signs and to obtain patient data previously only available through blood tests. The post Biosensors and Wearables…
-
New addiction society guidance on medetomidine’s brutal withdrawal
Clinicians first noticed medetomidine in the Philadelphia drug supply during the spring of 2024. There was a cluster of overdoses one weekend, leaving patients more sedated and with lower heart rates than normal after receiving the…
-
Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs
Windward Bio’s next-generation antibody drugs for immunology caught the interest of Sanofi, which bought shares in a private placement alongside the biotech’s IPO. Windward’s lead drug candidate addresses the same target as a blockbuster…
-
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
Despite all the setbacks, Boston Scientific won’t stop pushing the Watchman. The medical-device giant committed hundreds of millions to acquire the tiny heart implant more than a decade ago, and then endured a years-long debate at the Food…
-
What’s Missing from Healthcare Quality Conversations?
[Sponsored] Jason Tibbels, MD, Lantern Chief Medical Officer, described the company’s approach to making care more affordable without undermining quality or health outcomes in an interview with MedCity News Editor-in-Chief Arundhati Parmar…
-
STAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them . Don’t be shy…
-
STAT+: HHS plans funding for research into ibogaine for PTSD
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I’m plunging into psychedelia again — journalistically speaking. If you have any interesting tips on the matter…
-
Opinion: New organ donation rules are unfair to families
I watched Hailey’s chest without pause, searching for the slightest movement, a tiny intake of breath, any sign of life. Hailey (not her real name) was 22 years old, a college student who had suffered a catastrophic brain injury in a…
-
Brain implant startup pauses trials
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Buongiorno! Today’s stories have me wondering what it must be like to study the human brain: Every new discovery is a…
-
Pay Transparency in Life Sciences: Staying Ahead of Emerging Regulatory Complexity
In an industry characterized by intense competition for specialized and high-level talent and complex compensation structures, leaders must treat pay transparency not merely as a compliance requirement, but as a strategic priority…
-
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
-
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to tidy the Pharmalot grounds…
-
How Politics Became Every Hospital’s Brand Risk
When governments fall short on public health, hospitals inherit the fallout. Those with the strongest brands are best positioned to withstand it. The post How Politics Became Every Hospital’s Brand Risk appeared first on MedCity News .
-
This week in charts: Brain drugs are back on venture capitalists’ minds
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
-
STAT+: Senators introduce bill to curb conflicts of interest on preventive care panel
WASHINGTON — Two senators are introducing a bill Friday to rein in conflicts of interest on an influential federal panel that evaluates preventive medical services. The bill, from Sens. Angus King (I-Maine) and Elizabeth Warren (D-Mass.)…
-
The future of heart drug research in the wake of study setbacks
On this week’s episode of “The Readout LOUD”: the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest…
-
5 takeaways from STAT’s investigation of the sprawling ‘three-parent IVF’ industry
The investigation started with a tip from a British couple. After trying to have a second child for several years, they had signed up with a U.S.-based company called International Fertility Group (IFG), paying tens of thousands of dollars…
-
STAT+: Across the U.S., homegrown experiments aim to save kids from their phones
MILWAUKEE — Kat Zilka sat on the floor of her living room, beside a glowing Christmas tree and a pile of essays, and felt like weeping. It was late in 2022, and she had asked her 12th grade digital journalism students to reflect on their…
-
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated. Eli Lilly…
-
Opinion: STAT+: ‘What will I do with the time I have left?’: What it’s like to find out you might develop Alzheimer’s
This is the second of two pieces about the experiencing of pre-clinical Alzheimer’s. Read the first here . In 1976, at the dawn of the modern Alzheimer’s era, the neurologist Robert Katzman, champion of efforts to extract Alzheimer’s from…
-
Senator-elect Abdul El-Sayed on restoring trust in science, the state of public health, and RFK Jr.
Abdul El-Sayed will soon become the first epidemiologist in the Senate at a moment that would keep anyone with a public health background up at night. More than 5,000 Americans have been sickened by the measles this year and the United…
-
Windward prices $175M IPO to advance China-licensed lung drugs
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
-
A unified and practical taxonomy for false discovery rate control in omics research
Nature Biotechnology, Published online: 13 November 2026; doi:10.1038/s41587-026-03379-8 False discovery rate (FDR) control is central to omics research, yet the diverse procedures used rely on different assumptions. This Comment proposes…